HIMS Stock Recent News
HIMS LATEST HEADLINES
MIAMI, March 13, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs introduces RKLX and HIMZ, two 2X leveraged single-stock ETFs designed to provide amplified exposure to Rocket Lab USA, Inc. (NASDAQ: RKLB) and Hims & Hers Health Inc. (NYSE: HIMS). These ETFs offer traders a way to seek enhanced returns on Rocket Lab and Hims & Hers without requiring a margin account.
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $34.71, marking a +0.7% move from the previous day.
Roller-coaster healthcare stock Hims & Hers Health (HIMS 5.26%), whose stock got devastated last week by worries that it would be shut out of the GLP-1 market, got a reprieve from the Food and Drug Administration (FDA) on Monday.
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hims & Hers (HIMS -4.12%) is taking investors on a roller-coaster ride in 2025.
Hims & Hers (HIMS -4.12%) stock is down 50% from its peak earlier this year, but the drop in shares hasn't been driven by deteriorating operations. In fact, the company is growing as fast as ever.
This past week was rough for most investors, but it was a lot harder for a handful of cascading stocks. There were nearly a dozen U.S. exchange-listed companies with market caps north of $1 billion that tumbled by at least 20% last week.
Do you have more faith in DuPont analysis than simple ROE calculation? Tap Hims & Hers Health (HIMS), Blue Bird (BLBD), EMCOR Group (EME), EverQuote (EVER) and Sprouts Farmers Market (SFM).
Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase, and achieved $126 million in GAAP net income. The company's subscriber base reached 2.2 million, growing 45% year-over-year, with 55% of subscribers using at least one personalized treatment. Hims & Hers' GLP-1 weight loss treatments contributed $225 million in incremental revenue, but regulatory and supply risks remain significant concerns.
Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on Friday.